Maybe, maybe not. Every stock has a tipping point. This news is going to be reverberating throughout the US now. There is significant interest from CAR T players currently only able to treat blood cancers. This is a lucrative space and Imugene is attaining credibility at the forefront of this market segment. I bet Estrellas gains traction in the US after this presentation...
Ann: onCARlytics with Artemis T cells abstract presented at ASGCT, page-14
-
- There are more pages in this discussion • 82 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $334.7M | |||
| Open | High | Low | Value | Volume |
| 4.6¢ | 4.6¢ | 4.4¢ | $417.0K | 9.281M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 37 | 6074903 | 4.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.5¢ | 362283 | 5 |
View Market Depth
| Last trade - 16.10pm 07/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |